EGFR mutations in Latinos from the United States and Latin America.
| dc.contributor.author | Ariel López-Chávez | |
| dc.contributor.author | Moses O. Evbuomwan | |
| dc.contributor.author | Liqiang Xi | |
| dc.contributor.author | Guinevere Chun | |
| dc.contributor.author | Tatiana Vidaurre | |
| dc.contributor.author | Óscar Arrieta | |
| dc.contributor.author | George Oblitas | |
| dc.contributor.author | Ana B. Oton | |
| dc.contributor.author | Alejandro Calvo | |
| dc.contributor.author | Arun Rajan | |
| dc.coverage.spatial | Bolivia | |
| dc.date.accessioned | 2026-03-22T15:13:17Z | |
| dc.date.available | 2026-03-22T15:13:17Z | |
| dc.date.issued | 2015 | |
| dc.description | Citaciones: 4 | |
| dc.description.abstract | 8070 Background: Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to EGFR tyrosine kinase inhibitors in patients with advanced non–small-cell lung cancer (NSCLC). Racial and ethnic differences in the frequency of such mutations have been previously described; however, there are limited and conflicting reports on its frequency in the Latino population. Methods: We collected samples from 642 patients with NSCLC from 7 institutions in the US and Latin-America. Activating EGFR mutation analysis of exons 18 through 21 was performed at 2 CLIA certified central laboratories. Statistical analyses were performed using Fisher’s exact test or Mehta’s modification to Fisher’s exact test to determine relationships among parameters. All p-values are two-tailed and reported without adjustment for multiple comparisons. Results: EGFR mutation analysis was successfully performed in 480 of 642 patients (75%) of which 90 (19%) were Latinos, 318 (66%) non-Latino Whites, 35 (7%) non-Latino Asians, 30 (6%) non-Latino Blacks and 7 (2%) from other race/ethnicities. EGFR mutations were found in 21 of 90 (23%) Latino patients and its frequency varied according to country of origin. The highest frequency was observed in Latinos from Peru (37%) followed by US (23%), Mexico (18%), Venezuela (10%) and Bolivia (8%). In Latinos never smokers and Latinos with adenocarcinoma histology, the frequency of EGFR mutations was 38% and 30% respectively. There was a significant difference in the frequency of EGFR mutations among the different racial/ethnic subgroups analyzed (p < 0.001) with non-Latino Asians having the highest frequency (57%) followed by Latinos (23%), non-Latino Whites (19%) and non-Latino Blacks (10%). However, there was no difference between Latinos (23%) and non-Latinos (22%) (p = 0.78) and Latinos and non-Latino Whites (p = 0.37). While patients from Peru had an overall higher frequency of mutations (37%) than all other Latinos (17%), such difference was not statistically significant (p = 0.06) and diminished greatly when smoking and adenocarcinoma histology subgroups were analyzed independently. Conclusions: There was no significant difference between the frequency of EGFR mutations in NSCLC in Latinos and non-Latinos. | |
| dc.identifier.doi | 10.1200/jco.2015.33.15_suppl.8070 | |
| dc.identifier.uri | https://doi.org/10.1200/jco.2015.33.15_suppl.8070 | |
| dc.identifier.uri | https://andeanlibrary.org/handle/123456789/51093 | |
| dc.language.iso | en | |
| dc.publisher | Lippincott Williams & Wilkins | |
| dc.relation.ispartof | Journal of Clinical Oncology | |
| dc.source | Sylvester Comprehensive Cancer Center | |
| dc.subject | Medicine | |
| dc.subject | Exact test | |
| dc.subject | Lung cancer | |
| dc.subject | Internal medicine | |
| dc.subject | Demography | |
| dc.subject | Population | |
| dc.subject | Epidermal growth factor receptor | |
| dc.subject | Ethnic group | |
| dc.subject | Latin Americans | |
| dc.subject | Oncology | |
| dc.title | EGFR mutations in Latinos from the United States and Latin America. | |
| dc.type | article |